RT Journal Article
SR Electronic
T1 Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.08.22278547
DO 10.1101/2022.08.08.22278547
A1 Sophia T. Tan
A1 Ada T. Kwan
A1 Isabel Rodríguez-Barraquer
A1 Benjamin J. Singer
A1 Hailey J. Park
A1 Joseph A. Lewnard
A1 David Sears
A1 Nathan C. Lo
YR 2022
UL http://medrxiv.org/content/early/2022/08/09/2022.08.08.22278547.abstract
AB Breakthrough infections in vaccinated individuals and reinfections among previously infected individuals are increasingly prevalent, especially during the Omicron wave. Here, we analyze data from SARS-CoV-2 surveillance across 35 California prisons to understand the impact of vaccination and prior infection on infectiousness of individuals with SARS-CoV-2 Omicron infections in prison settings. We estimate that vaccination, prior infection, and both vaccination and prior infection reduced an index case’s risk of transmitting to close contacts by 24% (9-37%), 21% (4-36%) and 41% (23-54%), respectively. Booster vaccine doses and more recent vaccination further reduced infectiousness. These findings suggest that although vaccinated and/or previously infected individuals remain infectious upon SARS-CoV-2 Omicron infection in this prison setting, their infectiousness is reduced compared to individuals without any history of vaccination or infection.One Sentence Summary Vaccine-derived and naturally acquired immunity independently reduce the infectiousness of persons with Omicron SARS-CoV-2 infections.Competing Interest StatementJAL has received grants, honoraria, and speaker fees from Pfizer; grants and honoraria from Merck, Sharp, & Dohme; and honoraria from VaxCyte; all unrelated to the subject of this work. ATK and DS received funding from California Prison Health Care Receivership. The remaining authors have no disclosures.Funding StatementThe study was funded by the University of California, San Francisco Department of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the University of California, San Francisco gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests may be made to California Correctional Health Care Services (CCHCS) and are subject to controlled access. All analytic code is publicly available. https://github.com/sophttan/CDCR-CalProtect